PL4028396T3 - Sposób wytwarzania leku obejmującego pierścień oksepanowy - Google Patents
Sposób wytwarzania leku obejmującego pierścień oksepanowyInfo
- Publication number
- PL4028396T3 PL4028396T3 PL20776038.0T PL20776038T PL4028396T3 PL 4028396 T3 PL4028396 T3 PL 4028396T3 PL 20776038 T PL20776038 T PL 20776038T PL 4028396 T3 PL4028396 T3 PL 4028396T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- medicament containing
- oxepane ring
- oxepane
- ring
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 125000003551 oxepanyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898861P | 2019-09-11 | 2019-09-11 | |
| US201962934382P | 2019-11-12 | 2019-11-12 | |
| PCT/US2020/050086 WO2021050654A1 (en) | 2019-09-11 | 2020-09-10 | Process for the preparation of a medicament containing an oxepane ring. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4028396T3 true PL4028396T3 (pl) | 2024-04-29 |
Family
ID=72614037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20776038.0T PL4028396T3 (pl) | 2019-09-11 | 2020-09-10 | Sposób wytwarzania leku obejmującego pierścień oksepanowy |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11414412B2 (pl) |
| EP (1) | EP4028396B1 (pl) |
| JP (1) | JP7370457B2 (pl) |
| KR (1) | KR102786186B1 (pl) |
| CN (1) | CN114341134B (pl) |
| AU (1) | AU2020345916A1 (pl) |
| BR (1) | BR112022004455B1 (pl) |
| CA (1) | CA3147844A1 (pl) |
| CL (1) | CL2022000581A1 (pl) |
| CR (1) | CR20220100A (pl) |
| ES (1) | ES2972049T3 (pl) |
| IL (1) | IL291174B2 (pl) |
| MX (1) | MX2022002962A (pl) |
| MY (1) | MY208408A (pl) |
| PE (1) | PE20220709A1 (pl) |
| PL (1) | PL4028396T3 (pl) |
| SA (1) | SA522431923B1 (pl) |
| TW (1) | TWI856177B (pl) |
| WO (1) | WO2021050654A1 (pl) |
| ZA (1) | ZA202202178B (pl) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2635589A1 (en) * | 2010-11-03 | 2013-09-11 | Wockhardt Limited | Process for the preparation of phosphoric acid mono- (l-{4- [(s) -5- (acetylaminomethyl) - 2 - oxo - oxazolidin- 3 - yl]- 2, 6 - difluorophenyl} - 4 -methoxymethylpiperidin- 4 - yl) ester |
| AU2013322736A1 (en) * | 2012-09-26 | 2015-02-26 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| EP3119775B1 (en) * | 2014-03-18 | 2019-11-06 | F. Hoffmann-La Roche AG | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| SE540295C2 (en) * | 2016-12-05 | 2018-05-29 | Glactone Pharma Dev Ab | Sulfonamide analogues of galiellalactone |
-
2020
- 2020-09-09 TW TW109130966A patent/TWI856177B/zh active
- 2020-09-10 CR CR20220100A patent/CR20220100A/es unknown
- 2020-09-10 CA CA3147844A patent/CA3147844A1/en active Pending
- 2020-09-10 MY MYPI2022001035A patent/MY208408A/en unknown
- 2020-09-10 AU AU2020345916A patent/AU2020345916A1/en active Pending
- 2020-09-10 PL PL20776038.0T patent/PL4028396T3/pl unknown
- 2020-09-10 US US17/016,900 patent/US11414412B2/en active Active
- 2020-09-10 PE PE2022000381A patent/PE20220709A1/es unknown
- 2020-09-10 BR BR112022004455-0A patent/BR112022004455B1/pt active IP Right Grant
- 2020-09-10 IL IL291174A patent/IL291174B2/en unknown
- 2020-09-10 ES ES20776038T patent/ES2972049T3/es active Active
- 2020-09-10 CN CN202080062691.1A patent/CN114341134B/zh active Active
- 2020-09-10 WO PCT/US2020/050086 patent/WO2021050654A1/en not_active Ceased
- 2020-09-10 JP JP2022515639A patent/JP7370457B2/ja active Active
- 2020-09-10 EP EP20776038.0A patent/EP4028396B1/en active Active
- 2020-09-10 KR KR1020227008173A patent/KR102786186B1/ko active Active
- 2020-09-10 MX MX2022002962A patent/MX2022002962A/es unknown
-
2022
- 2022-02-21 ZA ZA2022/02178A patent/ZA202202178B/en unknown
- 2022-03-09 CL CL2022000581A patent/CL2022000581A1/es unknown
- 2022-03-10 SA SA522431923A patent/SA522431923B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114341134A (zh) | 2022-04-12 |
| KR102786186B1 (ko) | 2025-03-27 |
| BR112022004455A2 (pt) | 2022-06-14 |
| EP4028396B1 (en) | 2024-01-03 |
| IL291174B1 (en) | 2024-12-01 |
| IL291174A (en) | 2022-05-01 |
| CR20220100A (es) | 2022-05-23 |
| IL291174B2 (en) | 2025-04-01 |
| EP4028396C0 (en) | 2024-01-03 |
| PE20220709A1 (es) | 2022-05-04 |
| KR20220047324A (ko) | 2022-04-15 |
| JP2022547536A (ja) | 2022-11-14 |
| JP7370457B2 (ja) | 2023-10-27 |
| ES2972049T3 (es) | 2024-06-10 |
| MY208408A (en) | 2025-05-08 |
| SA522431923B1 (ar) | 2024-04-15 |
| BR112022004455B1 (pt) | 2024-04-30 |
| US20210070749A1 (en) | 2021-03-11 |
| WO2021050654A1 (en) | 2021-03-18 |
| TWI856177B (zh) | 2024-09-21 |
| ZA202202178B (en) | 2024-06-26 |
| EP4028396A1 (en) | 2022-07-20 |
| AU2020345916A1 (en) | 2022-03-03 |
| CL2022000581A1 (es) | 2022-10-07 |
| CN114341134B (zh) | 2024-03-08 |
| MX2022002962A (es) | 2022-09-29 |
| CA3147844A1 (en) | 2021-03-18 |
| US11414412B2 (en) | 2022-08-16 |
| TW202116309A (zh) | 2021-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102696B (en) | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof | |
| GB201903767D0 (en) | Multimers, tetramers & octamers | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| PH12020500105A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| PL3736228T3 (pl) | Kapsułka do przygotowania napoju, sposób jej wytwarzania i zastosowanie tej kapsułki | |
| GB2593352B (en) | Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone) | |
| IL289904A (en) | A process for preparing biphenylamines | |
| ZA202006907B (en) | A fatty preparation, a process for making said fatty preparation, and a product containing the same | |
| WO2016055647A3 (fr) | Procede de preparation de plasma universel | |
| IL283633A (en) | A process for preparing a cyclic dinucleotide | |
| IL286743A (en) | capsule for infusion products | |
| PL4037679T3 (pl) | Sposób wytwarzania walsartanu o wysokiej czystości | |
| IL291174A (en) | A process for preparing a drug containing an oxane ring | |
| IL286054A (en) | A process for the preparation of a modified imidazoquinoline | |
| ZA202102159B (en) | Process for the preparation of a flavouring | |
| PL3774752T3 (pl) | Sposób wytwarzania glicydolu | |
| EP3902982A4 (en) | NOZZLE RING STRUCTURE | |
| EP3273967A4 (en) | A process for the preparation of lorcaserin hydrochloride | |
| PL3725774T3 (pl) | Sposób wytwarzania środka farmaceutycznego | |
| ZA202006906B (en) | A fatty preparation, a process for making said fatty preparation, and a product containing the same | |
| IL288972A (en) | A continuous process for the preparation of anticholinergic drugs | |
| HK40063705A (en) | Medicament container | |
| EP4013502B8 (en) | Process for the preparation of a pyrimidino-diazepine derivative | |
| HK40042129A (en) | Single-serve capsule |